Novartis milestones be proud ! Management take a bow !

Discussion in 'Novartis' started by Anonymous, Jun 2, 2011 at 8:42 AM.

Tags: Add Tags
  1. Addios Alcon

    Addios Alcon Guest

    ANOTHER ONCE PROFITABLE BUSINESS NOVARTISIZED

    Thu Sep 15, 2016 | 9:38am EDT
    Novartis says 'never say never' to Alcon disposal
    By John Miller | ZURICH

    Novartis (NOVN.S) cannot rule out selling its Alcon eye care and surgery equipment division, its chief lawyer said on Thursday, helping fan speculation the Swiss drug company could offload a business that has been struggling to revitalize sales.

    General Counsel Felix Ehrat told a mergers and acquisitions conference in Zurich that Alcon's position as a leading surgical instruments maker fits Novartis's overall strategy of focusing on divisions which are among the largest players in their respective sectors.

    However, pressed on whether Novartis would rule out the prospect of an Alcon sale, Ehrat said at the conference organized by Swiss newspaper Finanz und Wirtschaft that such a pledge "wouldn't be clever".

    "Never say never," he added.

    Early this year Novartis Chief Executive Joe Jimenez replaced Alcon's chief executive following successive quarters of falling sales, attributing the poor performance to a lack of innovative new products and waning customer focus.

    The division's new boss Michael Ball is concentrating on top-line growth at the expense of profitability as he seeks to reinvigorate sales by year's end.

    But Alcon's poor performance and status as a device maker following the move this year of its ophthalmic drugs business into Novartis's main pharmaceuticals division, has fueled talk it is on the disposal block, especially if Ball's turnaround effort fails.

    "Alcon will either be fixed or sold," David Evans, an analyst at Kepler Cheuvreux, wrote in a recent note to investors.

    Sales have been in decline since 2014 at Alcon, which the Swiss drugmaker gradually bought up from food maker Nestle in a series of deals totaling $51 billion, with the final portion acquired at the end of 2015.

    Last year sales at Alcon fell 9 percent to $9.8 billion, including $3.8 billion from the drugs business which has since been moved out of the division.

    Novartis had sought to integrate the unit and its U.S.-centric culture - Alcon is based in Fort Worth, Texas - into the rest of the company, Ehrat said on Thursday, but a business model vastly different from the patent-protected world of drugs may have hampered the effort.

    "As the current, temporary difficulties may illustrate, not everything worked optimally," Ehrat said. "I wouldn't say that's a result of failed integration, rather the result of a not 100 percent successful integration."



    (Editing by Greg Mahlich)
     

  2. anonymous

    anonymous Guest

    What a paradox in which to find ourselves!!!

    "Never say never" doesn't make sense!!!
     
  3. anonymous

    anonymous Guest

    Pharmaceutical companies are fuelling the rise of superbugs by manufacturing drugs in factories that leak industrial waste, says a new report which calls on them to radically improve their supply chains.

    Factories in China and India – where the majority of the world’s antibiotics are produced – are releasing untreated waste fluid containing active ingredients into surrounding areas, highlights the report by a coalition of environmental and public health organisations.

    Ingredients used in antibiotics get into the local soil and water systems, leading to bacteria in the environment becoming resistant to the drugs. They are able to exchange genetic material with other nearby germs, spreading antibiotic resistance around the world, the report claims.

    Ahead of a United Nations summit on antimicrobial resistance in New York next week, the report – by the European Public Health Alliance (EPHA) and pressure group Changing Markets – calls on major drug companies to tackle the pollution which is one of its root causes.

    They say the industry is ignoring the pollution in its supply chain while it drives the proliferation of drug resistant bacteria – a phenomenon which kills an estimated 25,000 people across Europe and globally poses “as big a threat as terrorism,” according to NHS England’s Chief Medical Officer Dame Sally Davies.

    https://www.thebureauinvestigates.com/2016/09/15/big-pharmas-industrial-waste-fuelling-rise-superbugs-worldwide/
     
  4. anonymous

    anonymous Guest

    Send offending CEOs to jail.

    https://www.icc-cpi.int/itemsDocuments/20160915_OTP-Policy_Case-Selection_Eng.pdf

    The Office will also seek to cooperate and provide
    assistance to States, upon request, with respect to conduct which constitutes a
    serious crime under national law, such as the illegal exploitation of natural
    resources, arms trafficking, human trafficking, terrorism, financial crimes, land
    grabbing or the destruction of the environment.
     
  5. anonymous

    anonymous Guest

    Will the curtain never come down on these people?
     
  6. UnitedHealth dropped the latest formulary bomb Wednesday with a proposal to exclude Sanofi’s insulin Lantus and Amgen’s infection-fighter Neupogen in favor of their biosimilars.

    The insurer, among the top three in the U.S., also kicked off Novartis’ leukemia drug Gleevec, now that Sun Pharma has rolled out a generic version, and instituted step therapy on the Swiss drug giant’s Gleevec follow-up Tasigna.
     
  7. anonymous

    anonymous Guest

    Yes, I still need 4-6 weeks ;)
     
  8. anonymous

    anonymous Guest

    Looking forward to ththe show
    Thanks!
     
  9. HEALTH NEWS | Wed Oct 5, 2016 | 9:39am EDT
    Novartis reshapes research, closes some Swiss, Chinese units

    Novartis is closing some of its research operations in Switzerland and China and cutting 175 jobs, part of the Swiss drug maker's effort to centralize control over its drug discovery programs and contain costs.

    The Basel-based company is consolidating research oversight within its Swiss headquarters and the Novartis Institutes for Biomedical Research (NIBR) near Boston, now headed by Jay Bradner.

    In August, Novartis disbanded its stand-alone Cell and Gene Therapy unit, eliminating 120 mostly U.S. jobs
     
  10. anonymous

    anonymous Guest

    More to come without doubt
     
  11. Sandoz Can't Beat Blood Clot Drug Monopoly Suit
    By Dani Kass

    New York (September 30, 2016, 7:59 PM EDT) -- A Tennessee federal magistrate judge on Thursday recommended that a proposed class action accusing Momenta Pharmaceuticals Inc. and Sandoz Inc. of conspiring to monopolize the market for a generic of the blood clot drug Lovenox should stand, as a hospital sufficiently alleged that the companies manipulated the organization that sets quality testing standards.
     
  12. anonymous

    anonymous Guest


    http://www.finews.com/news/english-news/24608-joe-jimenez-novartis-ubs-creditsuisse-deutschebank
     
  13. anonymous

    anonymous Guest

  14. anonymous

    anonymous Guest

  15. anonymous

    anonymous Guest

    Novartis Pays More than $35 Million to Settle False Claims Case
    By Editor Filed in News October 5th, 2016 @ 3:48 pm
    Novartis Pharmaceuticals Corporation has paid more than $35 million to resolve federal and state False Claims Act allegations resulting from the off-label marketing for Elidel.

    [​IMG]

    Elidel is a cream approved by the Food and Drug Administration to treat eczema in patients older than two when conventional therapy is ineffective “or not advisable,” and only for short-term use.

    The settlement resolves a qui tam whistleblower case brought by former Novartis sales representative Donald Galmines.

    The case was filed in a Philadelphia federal court in July 2006.

    [​IMG]
    Donald Galmines

    “Off-label marketing” occurs when pharmaceutical companies work to convince physicians or other health care providers to prescribe medications for purposes, or for patient populations, unapproved by the FDA.

    Animal studies suggested that Elidel could cause skin cancer and non-Hodgkin’s lymphoma, and the FDA specifically refused to approve it for use on infants younger than 24 months.

    Most cases of eczema manifest during infancy, and are treated effectively with topical corticosteroids.

    Galmines alleged that he was instructed to tell doctors that Elidel was safe and effective for use on infants, and capitalize on what Novartis referred to as “steroid phobia” to boost the prescribing of Elidel.

    Galmines also alleged that Novartis violated federal and state kickback laws by paying physicians to attend lavish dinners and conferences where off-label uses of Elidel were advocated.

    “I thought that being a sales representative for Novartis was the best job I could ever have,” said Galmines, 44, of Frankfort, Illinois. “We were instructed that Elidel was so safe it could be put on up to 80% of a baby’s body. And we were never told that it might cause cancer.”

    As to the kickbacks, Galmines was trained to invite doctors and their families or staffs to dinners in expensive restaurants where Elidel might not even be discussed, in order to buy their loyalty.

    “Doctors told me that as long as the gifts kept coming, they’d prescribe to anyone I told them to,” Galmines said.

    ovartis’s marketing activities were so successful that in 2004, the FDA convened a “Pediatric Advisory Committee” to study the cancer risk and quell infant prescribing.

    In March 2005, FDA announced a “Black Box Warning” for Elidel.

    The Black Box is the FDA’s strongest advice to physicians and consumers regarding unapproved uses.

    In 2009, the federal and state governments decided not to intervene in the case, and Galmines pursued the litigation on their behalf.

    Galmines and his counsel litigated the case for several years.

    They reviewed of millions of sales-representative “call notes,” millions of pages of corporate documents, and testimony from almost two dozen witnesses.

    “The government only intervenes in about one in five whistleblower cases,” said Frederick Morgan, one of Galmines’s attorneys. “But the False Claims Act allows whistleblowers to go forward on behalf of the taxpayers if the government chooses not to take over.

    “We had no doubt that Mr. Galmines was right, and we viewed the marketing of this drug for use in infants as a serious matter which caused real harm to Medicaid beneficiaries and programs” Morgan said.

    The False Claims Act requires payment to successful whistleblowers of from 15% to 30% of the total recovery.

    The United States and states have paid Galmines 29% of the amounts they received from Novartis.

    Galmines also brought a separate case based on the off-label marketing of Elidel to treat infants in Texas, which is one of 30 states with their own qui tam fraud laws.

    That case was settled in 2012 for $19 million in damages and fees, bringing the total Galmines has recovered for state and federal taxpayers to more than $54 million.

    Galmines was represented by Frederick Morgan, Jennifer Verkamp, and Maxwell Smith of Morgan Verkamp in Cincinnati, and Marc Weingarten of Philadelphia.

    Novartis was represented by Michael Rogoff of Kaye Scholer in New York.
     
  16. anonymous

    anonymous Guest

    All time low is what I would love to say, but there's so much more to come that it's certain we are nowhere near rock bottom yet.
     
  17. anonymous

    anonymous Guest

    You have no idea LOL
    Coming soon to a theater near you ;)
     
  18. Novartis, Sanofi, NCI, Ranbaxy top missing data list as Shire most transparent
    by Ben Adams |
    Nov 4, 2016 4:43am

    A new, automated system coming out of the U.K.’s University of Oxford has named and shamed the worst culprits when it comes to not publishing trial data, with Big Pharma topping the list.

    The so-called TrialsTracker system found that, overall, 45.2% of trials conducted by major sponsors during the last decade are missing results. The biggest single culprits of this lack of reporting are:

    • Sanofi: failed to report on 65.5% of the trials it sponsored--285 trials missing out of 435
    • Novartis: failed to report on 37.6% of the trials it sponsored--201 trials missing out of 534
    • NCI: failed to report on 34.8% of the trials it sponsored--194 trials missing out of 558
    • Hôpitaux de Paris: failed to report on 63.7% of the trials it sponsored--186 trials missing out of 292
    • GSK: failed to report on 22.6% of the trials it sponsored--183 trials missing out of 809
     
  19. fire sale

    fire sale Guest

    Take a 50+ Billion acquisition , completely destroy it's value & yet keep your job aka Jimenez o_O

    DEALS | Sun Nov 13, 2016 | 7:12am EST
    Novartis chairman says considering sale of Alcon eye care division


    Drugmaker Novartis (NOVN.S) is considering to sell its struggling Alcon eye care division, its chairman said in an interview with Swiss weekly SonntagsZeitung.

    Novartis has blamed a failure to innovate and inconsistent customer service for the problems at Alcon, a business the company gradually bought from food maker Nestle in deals totaling $51 billion.

    Alcon will take longer to turn around than expected, Chief Executive Joe Jimenez said in October, forecasting unit sales to be flat to slightly down in the current quarter.

    "Alcon has not developed over the past two years as we had expected," Chairman Joerg Reinhardt said in an interview published on Sunday. Even though Novartis would continue to push the turnaround, all options were open in the future.

    "In the long run, the question arises as to whether we are the best owner for Alcon."